



Media Contact:
Melissa Neill
Java Culture Agency
(651) 295-6761

melissa@javacultureagency.com

FOR IMMEDIATE RELEASE

AK-FLUOR® Available Through Long Grove Pharmaceuticals®

FDA distribution agreement allows company to sell Fluorescein Injection, USP under AK-FLUOR® label

CHICAGO— Nov. 15, 2023 — Long Grove Pharmaceuticals, LLC, a manufacturer of differentiated pharmaceuticals, is filling a critical supply shortage of Fluorescein Injection, USP. In June 2023, Long Grove Pharmaceuticals acquired the New Drug Application (NDA) for AK-FLUOR. The company has reached a distribution agreement with the Food and Drug Administration (FDA) Office of Drug Shortages to make available existing inventory of AK-FLUOR, Fluorescein Injection, USP manufactured by Akorn Pharmaceuticals.

AK-FLUOR is indicated in diagnostic fluorescein angiography or angiography of the retina and iris vasculature. It is currently available in the following presentations:

- 10% (100mg/mL 5mL vials) 12 pack
- 25% (250mg/mL 2mL vials) 12 pack

Fluorescein Injection, USP is currently impacted by a supply shortage resulting from Akorn Pharmaceuticals' exit from the U.S. market. To ensure the consistent availability of Fluorescein Injection, USP prior to its relaunch as a Long Grove Pharmaceuticals product, Long Grove Pharmaceuticals will make available the existing AK-FLUOR inventory manufactured by Akorn Pharmaceuticals in both 10% and 25% solutions.

“Our goal is to provide the market a consistent supply of this essential medication now and after its relaunch as a Long Grove-labeled product,” said Peter Karas, Chief Commercial Officer at Long Grove Pharmaceuticals. “Until we can fill the gap in supply through our own manufacturing, the existing Akorn-manufactured product will assist in easing procurement burdens for ophthalmic providers and health systems.”

For more information about Long Grove Pharmaceuticals and AK-FLUOR, visit www.longgrovepharma.com.

###

About Long Grove Pharmaceuticals

Long Grove Pharmaceuticals was established in 2019 by Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry. The company is part of Capstone Development Services, which has been developing products in partnership with the

world's premier pharmaceutical and medical device organizations since 2013. Combining decades of collective leadership experience with a portfolio of specialized, complex generic drug formulations, Long Grove Pharmaceuticals is poised to innovate across the generic injectable and topical markets.